China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
One Percent Rule Checklist For Safer Forex Trading Risk 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
British drugmaker AstraZeneca Plc announced that Shenzhen Kangtai Biological Products would produce its potential COVID-19 vaccine in mainland China.
Under the agreement, Shenzhen Kangtai will ensure that it produces annually at least 100 million doses of AZD1222, an experimental shot that AstraZeneca co-developed with Oxford University researchers.
The deal highlights Astra's frontrunner position in delivering a COVD-19 vaccine, considering that Chinese ventures lead at least eight of the 26 global vaccine development projects.
The Shenzhen-based company, one of China's top vaccine makers, revealed via WeChat that it is mandated by the agreement to have the production capacity for at least 200 million doses by the end of 2021.
AstraZeneca said it would also explore cooperation with Shenzhen Kangtai in other markets.
The British pharmaceutical firm has signed manufacturing deals in the US, UK, South Korea, and Brazil for over two billion doses of the vaccine.
Other tie-ups between Chinese and Western players are between Fosun and Germany's BioNTech and Beijing Advaccine Biotechnology with Inovio Pharma.
Shenzhen Kangtai's main products are vaccines for Hepatitis B, flu and measles, and rubella.
